Results 41 to 50 of about 66,098 (241)
Brazilian Journal of Oncology, 2022 Objectives: To evaluate the efficacy between trastuzumab-only or pertuzumab plus trastuzumab therapies in metastatic HER2-positive breast cancer patients.
Kaline Nascimento dos Santos Lima +2 more
doaj +1 more source
Ultrasound microbubble-mediated CRISPR/Cas9 knockout of in HEC-1A cells
Journal of International Medical Research, 2019 Objective Epidermal growth factor receptor 2 (C-erbB-2) is one of the most frequently mutated oncogenes in human tumors. We aimed to evaluate the knockout efficiency of clustered regularly interspaced short palindromic repeat (CRISPR) technology using ...
Junhong Cai +3 more
doaj +1 more source
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. [PDF]
, 2016 Tumour resistance to radiotherapy remains a barrier to improving cancer patient outcomes. To overcome radioresistance, certain drugs have been found to sensitize cells to ionizing radiation (IR).
Adams, Stephen R +10 more
core +1 more source
Regulation of ErbB Receptors by the Ca2+ Sensor Protein Calmodulin in Cancer
Biomedicines, 2023 Overexpression and mutations of the epidermal growth factor receptor (EGFR/ErbB1/HER1) and other tyrosine kinase receptors of the ErbB family (ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4) play an essential role in enhancing the proliferation, the migratory ...
Antonio Villalobo
doaj +1 more source
Biophysical evidence for intrinsic disorder in the C-terminal tails of the epidermal growth factor receptor (EGFR) and HER3 receptor tyrosine kinases [PDF]
, 2016 The epidermal growth factor receptor (EGFR)/ErbB family of receptor tyrosine kinases includes oncogenes important in the progression of breast and other cancers, and they are targets for many drug development strategies.
Bose, Ron +5 more
core +2 more sources
The International Journal of Biological Markers, 1993 Selected murine monoclonal antibodies (MAb) have been shown to inhibit relevant tumor growth in vitro and in animal models. Recently, bispecific antibodies (BsMAb) have been developed which target cytolytic effector cells via one antibody binding site ...
I. Garcia De Palazzo +2 more
doaj +1 more source
hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. [PDF]
, 2015 Human Mena (hMENA), an actin regulatory protein of the ENA/VASP family, cooperates with ErbB receptor family signaling in breast cancer. It is overexpressed in high-risk preneoplastic lesions and in primary breast tumors where it correlates with HER2 ...
Circo, R +11 more
core +2 more sources
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. [PDF]
, 2014 BackgroundAfatinib is an oral, irreversible ErbB family blocker that has shown activity in epidermal growth factor receptor (EGFR)-mutated lung cancer.
Blackman, A +10 more
core +2 more sources
Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas
Breast Cancer Research, 2019 Background ERBB-2 is overexpressed in about 20% of breast cancers (BCs), indicating poor prognosis. The receptor activator of nuclear factor-κB (RANK) pathway is implicated in ERBB-2 (+) BC.
Ilianna Zoi +7 more
doaj +1 more source
Frontiers in Endocrinology, 2022 ObjectiveWe aimed to retrospectively collect pathologically identified pheochromocytoma and paraganglioma (PPGL) tumor tissues from our center and investigate the expression of apelin and succinyl-CoA synthetase subunit beta (SUCLG2), human epidermal ...
Yong Wang +8 more
doaj +1 more source